Technical Analysis for BCYC - Bicycle Therapeutics plc

Grade Last Price % Change Price Change
B 41.6 -2.37% -1.01
BCYC closed down 0.88 percent on Monday, September 27, 2021, on approximately normal volume.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Down
Historical BCYC trend table...

Date Alert Name Type % Chg
Bearish Engulfing Bearish -3.23%
MACD Bearish Signal Line Cross Bearish -3.23%
Inside Day Range Contraction -3.23%
Wide Bands Range Expansion -4.37%
Up 3 Days in a Row Strength -4.37%
Wide Bands Range Expansion -3.90%
Wide Bands Range Expansion -1.77%
Overbought Stochastic Strength -1.77%
Multiple of Ten Bullish Other -1.00%
Wide Bands Range Expansion -1.00%
Older End-of-Day Signals for BCYC ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
1.5x Volume Pace about 4 hours ago
Fell Below 20 DMA about 4 hours ago
20 DMA Support about 4 hours ago
Down 3% about 4 hours ago
10 DMA Resistance about 4 hours ago
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Bicycle Therapeutics plc Description

Bicycle Therapeutics Limited, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in preclinical studies targeting EphA2; BT8009, which is in preclinical studies targeting Nectin-4; and CD137, an immune cell co-stimulatory molecule that is in preclinical stage, as well as systemically-delivered activators. In addition, it is developing THR-149, a key immune cell co-stimulatory molecule that is in Phase I clinical trials. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, hematology, ophthalmology, and respiratory indications. The company has a clinical trial and license agreement with the Cancer Research Technology Limited and CRUK; and research collaboration agreement with Bioverativ Inc., AstraZeneca AB, and Oxurion NV. The company was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.


Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Life Sciences Immunology Diseases Oncology Ophthalmology Hematology Tumors Immune Checkpoint Cancer Research Search Technology

Is BCYC a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 45.21
52 Week Low 17.68
Average Volume 178,995
200-Day Moving Average 29.40
50-Day Moving Average 35.24
20-Day Moving Average 41.02
10-Day Moving Average 42.85
Average True Range 2.73
ADX 38.78
+DI 19.67
-DI 10.49
Chandelier Exit (Long, 3 ATRs) 37.01
Chandelier Exit (Short, 3 ATRs) 39.86
Upper Bollinger Bands 45.95
Lower Bollinger Band 36.09
Percent B (%b) 0.66
BandWidth 24.03
MACD Line 2.52
MACD Signal Line 2.66
MACD Histogram -0.1364
Fundamentals Value
Market Cap 907.8 Million
Num Shares 21.3 Million
EPS -14.16
Price-to-Earnings (P/E) Ratio -3.01
Price-to-Sales 30.77
Price-to-Book 3.85
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 46.09
Resistance 3 (R3) 46.38 45.50 45.51
Resistance 2 (R2) 45.50 44.62 45.36 45.32
Resistance 1 (R1) 44.06 44.07 43.62 43.77 45.12
Pivot Point 43.18 43.18 42.97 43.04 43.18
Support 1 (S1) 41.74 42.30 41.30 41.45 40.10
Support 2 (S2) 40.86 41.75 40.72 39.90
Support 3 (S3) 39.42 40.86 39.71
Support 4 (S4) 39.13